Forecast

Buy	1
Hold	0
Sell	0

News Go to news feed

Satellos appoints Antoinette Paone as chief development officer

Satellos appoints Antoinette Paone as chief development officer and head of regulatory affairs to advance development of its therapies for muscle diseases. Paone joins from Generation Bio, where she was most recently chief operating officer, and brings experience from a ten-year tenure at Vertex, where she led approval programs for cystic fibrosis therapies. Satellos is pursuing the orally administered agent SAT-3247 as a treatment for Duchenne muscular dystrophy; ongoing clinical trials in adults and children are intended to bring it closer to potential approval. » More on de.investing.com

Financials

In the last quarter, Satellos Bioscience had revenue of €0 and net profit of -€6.22M

(EUR)	Dec 2025	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-6.22M	-
EBITDA	-6.52M	-

Fundamentals

Metric	Value
Market capitalization	€83.38M
Number of shares	15.46M
52-week high/low	€10.79 - €0.76
Dividends	No
Beta	0.71
P/E ratio	-1.75
PEG ratio	-0.01
P/B ratio	0.49
P/S ratio	0.00

Company profile

Satellos Bioscience Inc. ist ein Unternehmen für regenerative Medizin und entwickelt Therapeutika zur Behandlung degenerativer Muskelkrankheiten. Das Hauptprogramm des Unternehmens konzentriert sich auf die Entwicklung eines oralen therapeutischen Medikaments zur Korrektur der Polarität von Muskelstammzellen und zur Wiederherstellung des körpereigenen Muskelreparatur- und Regenerationsprozesses. Das Unternehmen wurde 2012 gegründet und hat seinen Hauptsitz in Toronto, Kanada.